基于NNMT的膀胱癌尿液检测的临床性能及效用

Clinical performance and utility of a NNMT-based urine test for bladder cancer.

作者信息

Pozzi Valentina, Di Ruscio Giulia, Sartini Davide, Campagna Roberto, Seta Riccardo, Fulvi Paola, Vici Alexia, Milanese Giulio, Brandoni Gabriele, Galosi Andrea B, Montironi Rodolfo, Cecati Monia, Emanuelli Monica

机构信息

1 Department of Clinical Sciences, Polytechnic University of Marche, Ancona - Italy.

2 New York-Marche Structural Biology Center (NY-MaSBiC), Polytechnic University of Marche, Ancona - Italy.

出版信息

Int J Biol Markers. 2018 Jan;33(1):94-101. doi: 10.5301/ijbm.5000311.

DOI:10.5301/ijbm.5000311

PMID:29148015

Abstract

BACKGROUND

Bladder cancer (BC) represents the most common neoplasm of the urinary tract. Although cystoscopy and urine cytology represent the gold standard methods to monitor BC, both procedures have limitations. Therefore, the identification of reliable biomarkers for early and noninvasive detection of BC is urgently required.

METHODS

In this study, we analyzed nicotinamide N-methyltransferase (NNMT) expression in urine samples from 55 BC patients and 107 controls, using real-time polymerase chain reaction (PCR). Receiver operating characteristic (ROC) analysis was used to identify the best cutoff value to discriminate BC patients from healthy donors, and to evaluate the diagnostic accuracy of a urine-based NNMT test.

RESULTS

The results demonstrated that urinary NNMT expression was significantly (p<0.05) higher in BC patients. Moreover, a significant (p<0.05) inverse correlation was found between NNMT expression and histological grade. The ROC analysis revealed that a ΔCq of 13.3 was the best cutoff value, since it was associated with the highest combination of sensitivity and specificity. Moreover, the area under the curve (AUC) value was 0.913 (p<0.05), indicating the excellent diagnostic accuracy of a urine-based NNMT test.

CONCLUSIONS

Our data indicate that NNMT is a promising biomarker that could be used to support the early and noninvasive diagnosis of BC.

摘要

背景

膀胱癌（BC）是泌尿系统最常见的肿瘤。尽管膀胱镜检查和尿液细胞学检查是监测膀胱癌的金标准方法，但这两种方法都有局限性。因此，迫切需要鉴定用于膀胱癌早期和非侵入性检测的可靠生物标志物。

方法

在本研究中，我们使用实时聚合酶链反应（PCR）分析了55例膀胱癌患者和107例对照的尿液样本中烟酰胺N-甲基转移酶（NNMT）的表达。采用受试者工作特征（ROC）分析来确定区分膀胱癌患者和健康供体的最佳临界值，并评估基于尿液的NNMT检测的诊断准确性。

结果

结果表明，膀胱癌患者尿液中NNMT表达显著升高（p<0.05）。此外，NNMT表达与组织学分级之间存在显著的负相关（p<0.05）。ROC分析显示，ΔCq为13.3是最佳临界值，因为它与最高的敏感性和特异性组合相关。此外，曲线下面积（AUC）值为0.913（p<0.05），表明基于尿液的NNMT检测具有出色的诊断准确性。